PMEF
ALLO icon

Point72 Middle East FZE’s Allogene Therapeutics ALLO Stock Holding History

Point72 Middle East FZE’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-127,237
Closed -$408K – 71
2023
Q4 		$408K Buy
+127,237
New +$361K 0.01% 873
2023
Q3 		– Sell
-54,242
Closed -$270K – 1416
2023
Q2 		$270K Buy
54,242
+45,839
+546% +$248K 0.01% 958
2023
Q1 		$41.5K Sell
8,403
-47,817
-85% -$307K ﹤0.01% 1297
2022
Q4 		$354K Buy
+56,220
New +$520K 0.02% 860

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Middle East FZE's ALLO Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 127,237 shares — an estimated $408K sold.

Point72 Middle East FZE first reported a position in ALLO in Q4 2022 and held it in 4 quarters. The position peaked at $408K in Q4 2023. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 127,237 Allogene Therapeutics shares in Q1 2024, an estimated $408K.
  • Point72 Middle East FZE first reported a position in Allogene Therapeutics in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Allogene Therapeutics position peaked at $408K in Q4 2023.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.